Boston Scientific Corp. said the FDA approved three products in its Cardiac Rhythm Management business, including the CONFIENT implantable cardioverter defibrillator (ICD), the LIVIAN cardiac resynchronization therapy defibrillator (CRT-D) and an upgraded LATITUDE Patient Management System.
The CONFIENT ICD reportedly features an enhanced AV (atrial ventricular) Search Hysteresis designed to reduce unnecessary right ventricular pacing.
The LIVIAN CRT-D reportedly enables physicians to provide patients with individualized therapy using SmartDelay technology, which enables physicians to tailor individualized pacing therapies for their patients. The upgraded LATITUDE Patient Management System also has enhanced remote monitoring capabilities.